LumiraDx submits SARS-CoV-2/flu A/B rapid antigen test for EUA

Create PDF

November 2021—LumiraDx has submitted the LumiraDx SARS-CoV-2 and Flu A/B Test to the Food and Drug Administration for emergency use authorization.

The test is a rapid microfluidic immunofluorescence assay intended for the simultaneous detection of SARS-CoV-2, influenza A, and influenza B viral antigen direct from self- or clinician-collected nasal swab specimens within the first 12 days of the onset of symptoms. Results are available in 12 minutes from sample application on the LumiraDx point-of-care platform.